Showing posts with label Schizophrenia. Show all posts
Showing posts with label Schizophrenia. Show all posts

Saturday, June 13, 2015

Schizophrenia, bipolar disorder may share genetic roots with creativity

Although creativity is difficult to define for scientific purposes, researchers consider a creative person to be someone who takes novel approaches requiring cognitive processes that are different from prevailing modes of thought or expression. Schizophrenia and bipolar disorder are disorders of thoughts and emotions, which means that those affected show alterations in cognitive and emotional processing.
Credit: © postsmth / Fotolia
Genes linked to creativity could increase the risk of developing schizophrenia and bipolar disorder, according to new research carried out by researchers at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London.
Previous studies have identified a link between creativity and psychiatric disorders such as bipolar disorder, but it has remained unclear whether this association is due to common genes. Published in Nature Neuroscience, this new study lends support to the direct influence on creativity of genes found in people with schizophrenia and bipolar disorder.
Although creativity is difficult to define for scientific purposes, researchers consider a creative person to be someone who takes novel approaches requiring cognitive processes that are different from prevailing modes of thought or expression. Schizophrenia and bipolar disorder are disorders of thoughts and emotions, which means that those affected show alterations in cognitive and emotional processing.
It has long been suggested that creativity and psychosis show certain similarities, with notable examples of artists such as Vincent Van Gogh who themselves suffered from psychiatric illnesses. Previous studies have shown that psychiatric disorders, particularly bipolar disorder, tend to be found in the same families where creative professions are common. However, until now it had not been possible to pinpoint whether this was simply due to shared environmental factors or socioeconomic status.
Genetic risk scores were examined in a sample of 86,292 individuals from the general population of Iceland, in collaboration with researchers from deCODE Genetics, who provided the data. Creative individuals were defined as those belonging to the national artistic societies of actors, dancers, musicians, visual artists and writers.
Researchers found that genetic risk scores for both schizophrenia and bipolar disorder were significantly higher in those defined as creative individuals, with scores approximately halfway between the general population and those with the disorders themselves.
These findings lend support to the direct influence of genetic factors on creativity, as opposed to the effect of sharing an environment with individuals who have schizophrenia or bipolar disorder.
Robert Power, first author from the MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre at the IoPPN, said: 'For most psychiatric disorders little is known about the underlying biological pathways that lead to illness. An idea that has gained credibility is that these disorders reflect extremes of the normal spectrum of human behaviour, rather than a distinct psychiatric illness. By knowing which healthy behaviours, such as creativity, share their biology with psychiatric illnesses we gain a better understanding of the thought processes that lead a person to become ill and how the brain might be going wrong.'
'Our findings suggest that creative people may have a genetic predisposition towards thinking differently which, when combined with other harmful biological or environmental factors, could lead to mental illness.'

Story Source:
The above story is based on materials provided by King's College London.Note: Materials may be edited for content and length.
Continue to Read more ...

Saturday, April 4, 2015

How important is the name of a disease? Do names influence treatment?

There are a number of factors that can alter the manner in which a disease and its patients are treated. The opinions of patients, clinicians and policymakers can all have an impact, but to what extent are these affected by the name of a disease?

Health registration form.
Can a name affect the kind of treatment that patients can expect to receive?
In Shakespeare's Romeo and Juliet, it is claimed "that which we call a rose by any other name would smell as sweet." But would someone's reaction to a rose be different if, for example, they were instead named "stink blossoms," as suggested by Bart Simpson in an episode of The Simpsons?
This might be a slightly silly and trivial example, but it serves to make a point. The way in which objects and people are perceived can be altered purely on account of their name.
If offered a choice of two hospitals to visit without seeing any credentials, I would certainly be more inclined to visit the "Good Heart Clinic" over "Dr. Giggles' Bouncy Fun Hospital." But outside of extreme hypothetical decisions such as this, what extent does this form of bias exist within medicine?
Some diseases have got reputations so fearsome that clinicians avoid speaking their names. A recent report from the Alzheimer's Association found that many health care providers decided against disclosing a diagnosis of Alzheimer's disease due to the fear of causing a patient or their caregivers distress.
Last month, the Institute of Medicine (IOM) convened a committee of health experts that proposed new diagnostic criteria and a new name for chronic fatigue syndrome. The changes were recommended to more accurately reflect the main characteristics of the condition and improve levels of treatment.
In this Spotlight article, we take a look at these recommendations and examine the reactions they have received from patients and clinicians alike. We will also examine a number of other examples of medical name changes from around the world in order to assess just what is in a name.

Introducing 'systemic exertion intolerance disease'

The IOM-convened committee suggested that previous names myalgic encephalomyelitis (ME) and chronic fatigue syndrome(CFS) may have contributed to misconceptions about the illness.
Encephalomyelitis refers to brain inflammation, and there is a lack of evidence to suggest that the illness causes this to occur in patients. Myalgia - muscle pain - is also not considered to be a core symptom of the disease. Similarly, previous research has suggested that the name "chronic fatigue syndrome" could lead to the disease being trivialized.
"Due to the stigma in the name 'chronic fatigue' just about everyone wrote off my newly discovered syndrome, causing a major loss in friendships, relationships, jobs, etc.," reports Lindsey Beres, the founder of Bent But Not Broken, a nonprofit organization dedicated to providing support to patients with the disease and their caregivers.
The IOM committee recommended that a new, more representative name be adopted - systemic exertion intolerance disease (SEID):
"This name captures a central characteristic of the disease: the fact that exertion of any sort - physical, cognitive or emotional - can adversely affect patients in many organ systems and in many aspects of their lives. The committee believes systemic exertion intolerance disease appropriately captures the complexity and severity of the illness."
For Beres, the announcement was a positive one. "Calling it a disease instead of a syndrome and getting national attention vindicates my years of failed explanations attempts," she writes.
The recommendation was still made only recently, and so it is likely that its impact will not be measurable for a considerable amount of time. Beres told Medical News Today that Bent But Not Broken expect the name change will take a while to be fully adopted, "so we will continue using CFS/SEID to describe the patients we serve for the time being."
How might this recommendation and potential widespread adoption of the new name affect treatment of the disease? The answer to this question could be found in a previous instance of renaming that occurred in Japan in 2002.

The problem with 'mind-split-disease'

Schizophrenia is a chronic mental disorder that can be severely disabling to those who develop it. It is characterized by a range of deficits in emotional responsiveness, perceptions and thought processes.
Woman with eight faces.
The belief that all people with schizophrenia have split personalities is just one common misconception about the disorder.
In a Spotlight article last year, MNT found that there is a large amount of public misunderstanding around the disease, with many people mistakenly believing that schizophrenia means having a split personality or a violent temperament.
A report conducted in 1999 even reported that 61% of Americans believed people with schizophrenia were likely to be violent toward other people.
These misperceptions may have been caused by a combination of media portrayals of the disease and the name itself. The word comes from the Greek words skhizein meaning "to split" and phren meaning "mind." While this term was originally intended to suggest a fragmented way of thinking, it lends itself readily to the idea of split or multiple personalities.
In Japan, schizophrenia used to be referred to as Seishin Bunretsu Byo, translating as "mind-split-disease." In a paper published in World Psychiatry, Prof. Mitsumoto Sato describes how many psychiatrists were reticent to inform patients of a schizophrenia diagnosis because of the negative consequences such a diagnosis could confer.
"The old term identified the patient as a person with a disorganized personality even after recovery or full remission. That is, once the diagnosis of 'Seishin Bunretsu Byo' was made, the patient was usually regarded as an essentially ill person throughout his or her life," writes Sato.
A new term Togo Shitcho Sho, translating as "integration disorder" was introduced by the Japanese Society of Psychiatry and Neurology in 2002, following a request from a patients' families group.
"The new term for schizophrenia ("Togo Shitcho Sho") refers to the vulnerability-stress model, and implies that the disorder may be treated and that recovery is possible if a combination of advanced pharmacotherapy with appropriate psychosocial intervention is used," Sato explains.
Seven months after the renaming, a survey found that the new term had replaced the old in around 78% of cases. The percentage of cases in which patients were fully informed of their diagnosis rose from 36.7% to 69.7% over the course of 3 years.
A survey of the Miyagi College of Psychiatrists also reported that 82% of respondents found the new name better for obtaining patient consent, improving treatment compliance, reducing stigma and achieving social integration for patients.

Negative reactions to the proposed renaming of ME/CFS

These outcomes suggest that the renaming of schizophrenia in Japan has been a success, and it is perhaps not surprising that there have been calls to rename the disease elsewhere.
In Korea, for example, a new term has also been coined to replace "mind-splitting disease" with "attunement disorder." "This term literally refers to tuning a string instrument, and metaphorically it describes schizophrenia as a disorder caused by mistuning of the brain's neural network," explain the authors of a study published in the Asian Journal of Psychiatry.
Not everyone is supportive of change, however. Concerning schizophrenia, Jeffrey A. Lieberman and Michael B. First argue in an article published in The BMJ that renaming schizophrenia would not have the desired effect:
"Unfortunately, changing the name of the condition (or even abolishing the concept) will not affect the root cause of the stigma - the public's ignorance and fear of people with mental illness. Renaming may even have the unintended effect that the person, rather than the illness, is blamed for the symptoms."
The proposed renaming of ME/CFS to SEID has also provoked some negative responses from clinicians and the general public alike.
In the comments section of MNT's article about the recommendations, readers have described the proposals as "absurd," "less descriptive" and could set back treatment of the condition by another 20 years.
Prof. Leonard A. Jason, a professor of psychology at DePaul University, Chicago, IL, recently wrote a blog post addressing the recommended name change and he states the reaction he had received from patients "was mixed at best."
"Our research group has found that a more medically-sounding term like ME is more likely to influence medical interns to attribute a physiological cause to the illness," Prof. Jason writes. And while the term ME is deemed to be medically inaccurate, he argues that many other diseases that are accepted have inaccurate names. Malaria, for example, means "bad air."
Prof. Jason suggests that the recommendation was made without proper consultation with the public, the committee making critical decisions in a secretive process. While this approach may be necessary for some IOM initiatives, "in this area - due to patients being historically excluded and disempowered - there was a need for a more transparent, interactive and open process."
A more inclusive approach to instigating a name change was demonstrated by the Association of Early Pregnancy Units (AEPU) and the Miscarriage Association in the UK. The publication of a charter for miscarriage care by the online organization Mumsnet suggested there was a need for more sensitive terminology in British health care.
In particular, the commonly used term evacuation of retained products of conception was found to be both upsetting and confusing by women and their partners. A research team conducted several online surveys targeting both health professionals and patients and found there was an overwhelming interest in changing this term.
The surveys found that the alternative term surgical management of miscarriage (SMM) was the most popular, and it has since been recommended by the AEPU and the Miscarriage Association that the term should be introduced as standard in the UK.

'I am excited for the awareness it has brought to the disease'

Although there has been negativity from some quarters to the recommended name change for ME/CFS, there have also been positive reactions. At the forefront of this positivity appears to be the implication that the proposed name change has now legitimized the disease.
Patients in a waiting room.
Only time will whether the recommended new name for ME/CFS will lead to improved research and rates of diagnosis.
"To some, the IOM report may not sound like a major feat, but to longtime supporters, sufferers, and researchers of CFS/SEID, the attention surrounding the report is exactly what they have been striving for," writes Deanna Lee for Bent But Not Broken. "For the first time, CFS/SEID is relevant and it is getting national coverage."
Lindsey Beres was surprised by the negative reaction to the proposed name, having expected more positive comments or celebrations of recognition. "Personally, I am not a huge fan of the name," she told MNT, "but I am excited for the awareness it has brought to the disease."
The nonprofit organization is already feeling the impact of this raised awareness. Bent But Not Broken report an increase in their receipt of financial application submissions, patient testimonials and overall interest in the disease since the IOM's recommendation was made.
"Regardless of your feelings about the name, try to look past just the title and look at the implications for research, funding, backing, social legitimacy, treatments and insurance coverage," Beres writes.
Beres told MNT she believes education, acceptance and clinical adoption of the disease within the medical community are major problems for the treatment of CFS/SEID that are yet to be addressed.
"Once practitioners believe in the condition and the ranges of severity, then proper diagnosis can occur," she said. "Once that happens, I believe having a full range of treatment options available is the next step."
In the IOM report, the committee states that many people struggle with their symptoms for years before receiving a diagnosis. Bringing the disease back to the attention of health care providers could be a surefire way of improving this situation.
Despite the flaws in the recommended new name, it is clear that there are potential benefits to be had. While it can be difficult to accurately label conditions such as CFS/SEID and schizophrenia that can affect patients in a wide variety of different ways, it is important that people - both clinicians and patients alike - are aware of them.
The renaming of schizophrenia in Japan suggests that the naming of a disease can have a positive impact on how it is treated. Only time will tell what the impact of the IOM's recommendations for CFS/SEID will be, but there is hope that, despite some criticism, it could be a change that benefits between 836,000 and 2.5 million Americans estimated to have the disease.
Continue to Read more ...

Monday, August 6, 2012

INVEGA(TM) Approved By FDA As New Treatment For Schizophrenia

The U.S. Food and Drug Administration (FDA) has approved INVEGA(TM) (paliperidone) Extended-Release Tablets, a new atypical antipsychotic, for the treatment of schizophrenia. The once-daily oral medication is specifically designed to deliver paliperidone -- the active ingredient derived from risperidone -- through the innovative OROS(R) extended-release technology, demonstrating powerful efficacy and a proven safety and tolerability profile. INVEGA will be marketed by Janssen, L.P., based in Titusville, N.J. and will be available in the U.S. in January 2007.

"A well-designed series of worldwide clinical trials involving more than 1,600 patients in 23 countries, have demonstrated that INVEGA provided significant improvement in multiple domains for the symptoms of schizophrenia," said Henry Nasrallah, M.D., Professor of Psychiatry and Neuroscience and Director of the Schizophrenia Research Program at the University of Cincinnati Academic Health Center. "In addition, in these clinical trials, INVEGA demonstrated not only efficacy in treating the symptoms of schizophrenia, but also improvement in the Personal and Social Performance (PSP) Scale, which measures personal and social functioning. At the recommended dose of 6 mg per day, INVEGA had a tolerability profile that was similar to placebo."

Leading national mental health advocacy and patient organizations also recognize the importance of new treatments for schizophrenia.

"We are pleased that innovative delivery technologies are being applied to new treatments for schizophrenia," said Michael J. Fitzpatrick, MSW, Executive Director, National Alliance on Mental Illness (NAMI). "New and efficacious treatment options, like INVEGA, provide significant opportunities for more people with schizophrenia to manage their disease as they work with their treatment teams to live more fulfilling and productive lives."

INVEGA is the first new prescription treatment for schizophrenia to be approved by the FDA since 2003.

The primary measure of efficacy was the Positive and Negative Syndrome Scale (PANSS), a tool commonly used in schizophrenia research that measures the severity of positive and negative symptoms. Personal and Social Performance, another measure of efficacy, as well as safety and tolerability were also included in the trials that supported the approval of INVEGA. The recommended dose of INVEGA is 6 mg per day, with a dose range of 3 mg to 12 mg per day, depending on patient need.

Key findings of the program include:

In six week clinical trials, INVEGA demonstrated statistically significant symptom improvement versus placebo across all doses investigated. INVEGA was also superior to placebo on the PSP in these trials. INVEGA is the first treatment for schizophrenia to receive FDA approval to include PSP in product labeling.


Treatment-emergent adverse events(i) (TEAEs) reported in 5% or more of subjects treated with INVEGA and at least twice the placebo rate for at least one dose included: akathisia (i.e. restlessness) and extrapyramidal disorder (e.g. involuntary movements, tremors or muscle stiffness).

Discontinuation rates due to TEAEs for all INVEGA dose groups were low and comparable to placebo (5% for placebo and for INVEGA: 2% for 3 mg, 6% for 6 mg, 4% for 9 mg, 5% for 12 mg).

INVEGA(TM) (paliperidone) extended-release tablets is indicated for the treatment of schizophrenia.

RISPERDAL(R) (risperidone) Tablets/Oral Solution/Orally Disintegrating Tablets is indicated for the treatment of irritability associated with autistic disorder in children and adolescents (ages 5-16 years), including symptoms of aggression towards others, deliberate self-injury, tantrums, and quickly changing moods.

RISPERDAL(R) (risperidone) is indicated for the treatment of schizophrenia and for the treatment of manic symptoms of acute manic or mixed episodes associated with bipolar I disorder.

IMPORTANT SAFETY INFORMATION FOR INVEGA(TM) AND RISPERDAL(R)

Elderly Patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. INVEGA (paliperidone), and RISPERDAL (risperidone) are not approved for the treatment of patients with Dementia-Related Psychosis.

Schizophrenia:

The most common side effects that occurred with INVEGA were restlessness and extrapyramidal disorder (for example, involuntary movements, tremors and muscle stiffness). The most common side effects that occurred with RISPERDAL were anxiety, sleepiness, restlessness, tremors, and muscle stiffness; dizziness, constipation, nausea, indigestion, runny nose, rash, and rapid heartbeat.

Bipolar Mania:

The most common side effects that occurred in clinical trials with RISPERDAL, in the treatment of bipolar mania either alone or in combination with a mood stabilizer (lithium or valproate) were: sleepiness, muscle stiffness, restlessness, tremor, indigestion, nausea, abnormal vision, muscle aches, dizziness, runny nose, diarrhea, increased saliva, stomach pain, and urinary incontinence.

Autistic Disorder:

The most common side effects that occurred with RISPERDAL were sleepiness, increased appetite, fatigue, upper respiratory tract infection, increased saliva, constipation, dry mouth, tremor, muscle stiffness, dizziness, repetitive behavior, involuntary movement, rapid heartbeats, confusion, weight increase.

One risk of INVEGA is that it may change your heart rhythm. This effect is potentially serious, and you should talk to your doctor about any current or past heart problems. Please inform your healthcare professional of any medications or supplements that you are taking.

A rare but serious side effect that has been reported with this kind of medicine, including INVEGA, and RISPERDAL, is known as neuroleptic malignant syndrome (NMS). NMS is characterized by muscle rigidity, fever and can be serious.

You may have heard the term "tardive dyskinesia." These are usually persistent, uncontrollable, slow or jerky facial or body movements that can be caused by all medications of this type. If you have these symptoms, talk to your healthcare professional.

Studies suggest an increased risk of elevated blood sugar-related side effects, and sometimes potentially fatal, in patients treated with this class of medications, including INVEGA and RISPERDAL. Some people may need regular blood sugar testing.

People with narrowing or blockage of the gastrointestinal tract (esophagus, stomach or small or large intestine) should talk to their healthcare professional before taking INVEGA.

Some people taking INVEGA or RISPERDAL may feel faint or lightheaded when they stand up or sit up too quickly. By standing up or sitting up slowly and following your healthcare professional's dosing instructions, this side effect may be reduced or it may go away over time.

You may have heard the term "extrapyramidal symptoms" (EPS). These are usually persistent movement disorders or muscle disturbances, such as restlessness, tremors, and muscle stiffness. Some people taking INVEGA or RISPERDAL have these side effects. If you have these symptoms, talk to your healthcare professional.

Some medications may interact with INVEGA or RISPERDAL. Avoid alcohol while on INVEGA or RISPERDAL.

Inform your healthcare professional if you are pregnant or if you are planning to get pregnant while taking INVEGA or RISPERDAL. Do not breast-feed if you are taking INVEGA or RISPERDAL.

INVEGA or RISPERDAL may affect your driving ability, therefore, do not drive or operate machines before talking to your healthcare professional.

NVEGA and RISPERDAL may affect alertness and motor skills; use caution until the effect of INVEGA and RISPERDAL is known.

INVEGA may make you more sensitive to heat. You may have trouble cooling off, or be more likely to become dehydrated, so take care when exercising or when doing things that make you warm.

INVEGA should be swallowed whole. Tablets should not be chewed, divided, or crushed. Do not be worried if you see something that looks like a tablet in your stool. This is what is left of the tablet after all the medicine has been released.

Please see full important U.S. prescribing information for INVEGA and RISPERDAL at http://www.janssen.com.

Worldwide, it is estimated that one person in every 100 develops schizophrenia, one of the most serious types of mental illness. In the United States, there are currently two million people with schizophrenia, with men and women affected equally. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions and social withdrawal), as well by disorganized thinking.

The FDA is the first regulatory agency worldwide to approve INVEGA. Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) submitted a New Drug Application to the FDA in November 2005. In May 2006, Janssen-Cilag, NV submitted a Marketing Authorization Application to European health authorities seeking approval to market the medication for the treatment of schizophrenia and approvals will be sought worldwide.

Janssen, L.P., based in Titusville, N.J., is the only pharmaceutical company in the U.S. dedicated solely to mental health. The company currently markets prescription medications for the treatment of schizophrenia, bipolar mania and irritability associated with autistic disorder. For more information about Janssen, L.P., visit http://www.janssen.com, and for more information on INVEGA, visit http://www.INVEGA.com.

J&JPRD is headquartered in Raritan, NJ, and has facilities throughout Europe and the U.S. The company is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide.

INVEGA delivers paliperidone via the OROS extended-release technology, which was developed by ALZA Corporation. OROS technology employs osmosis to provide precise, controlled drug delivery. For more information on OROS technology, please visit: http://www.alza.com.

Web sites: http://www.janssen.com; http://www.invega.com; http://www.alza.com; http://www.jnj.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

i) A treatment-emergent adverse event is defined as any event not present prior to the initiation of the treatments or any event already present that worsens in intensity or frequency following exposure to the treatments.

Janssen, L.P.
http://www.janssen.com
Continue to Read more ...

Exposure To "Thin-Idea" Media Affecting Women's Standards Of Body Image

New research explores the relationship between so called "thin-ideal" images in the media and body-image issues among young women. Female undergraduates who viewed advertisements displaying ultra-thin women exhibited increases in body dissatisfaction, negative mood, levels of depression and lowered self-esteem. These findings were particularly true for women who have negative views of their current body image and believe themselves to be overweight.

The study shows that women who possess these body image concerns are twice as likely to compare their own bodies to those of the thin models in the advertisements. They are also more likely to have those comparisons affect their self-worth, leading to feelings of depression, body dissatisfaction and preoccupation with diet and exercise. Conversely, women who are content with their bodies did not show any effects from viewing thin-ideal advertisements.

"Women who already have low opinions of their physical appearance are at an even greater risk for negative effects from media images," says Gayle R. Bessenoff, Ph.D., author of the study. "Understanding who will compare to media ideals and when this comparison will take place can help further our understanding of the role of the media in the development of eating disorders."

###

This study is published in the current issue of Psychology of Women Quarterly.

Gayle R. Bessenoff, Ph.D., a professor in the Psychology Department of the University of Connecticut and has more than 7 years of research experience in the fields of social comparison, body image and women in the media.

Psychology of Women Quarterly is a feminist journal that publishes research with substantive and theoretical merit, along with critical reviews, theoretical articles, and invited book reviews related to the psychology of women and gender. Topics include career choice and training; management and performance variables; education; lifespan role development and change; physical and mental health and well-being; physical, sexual, and psychological abuse; violence and harassment; prejudice and discrimination; psychobiological factors; sex-related comparisons; sexuality, sexual orientation, and heterosexism; social and cognitive processes; and therapeutic processes. For more information, please visit: http://www.blackwell-synergy.com/loi/pwqu

Blackwell Publishing is the world's leading society publisher, partnering with 665 academic and professional societies. Blackwell publishes over 800 journals and, to date, has published more than 6,000 books, across a wide range of academic, medical, and professional subjects. Please visit http://www.blackwellpublishing.com/ for more information.
Continue to Read more ...
Related Posts Plugin for WordPress, Blogger...

Popular Posts